The broker cited stretched valuations and slower-than-expected traction in speciality drugs. It flagged concerns around ...

Sun Pharmaceutical Industries Ltd. 524715 shares inched up 0.20% to 1,642.90 Indian rupees Friday, on what proved to be an ...

Indian stock market indices Sensex and Nifty plunged significantly due to concerns over US tariffs and foreign fund outflows, ...

Documents obtained by ProPublica offer a rare glimpse into discussions between the global drugmaker Sun Pharma and the FDA, ...

A trio of Indian drugmakers—Alembic Pharmaceuticals, Sun Pharmaceutical and Glenmark Pharmaceuticals—issued separate ...

Bank of America downgraded Sun Pharma stock to ‘underperform’ from ‘neutral’, citing risks to premium valuations and slower ...

BoFA values the stock at 32 times FY27 earnings against its 10-year average of 25.5 times, reflecting its transition to ...

Sun Pharmaceutical Industries' shares fell by 2.29% to Rs 1,618.70 during Tuesday's early trading, despite consistent financial growth over recent years.

Sun Pharmaceutical shares dropped by 2.8% after Bank of America downgraded the stock due to concerns over premium valuations and slower speciality execution.

Sun Pharmaceutical Industries Ltd. closed 17.04% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

While many campaigns for plaque psoriasis treatments focus on erasing the external effects of the condition, Sun Pharma’s latest Ilumya push is emphasizing the importance of looking inward, too.

At the current price, shares of Sun Pharma are trading at a financial year 2027 price-to-earnings multiple of 32 times, which ...